The Efficacy and Safety of Sirolimus -Coated Balloon (SeQuent® SCB) in Treatment of Patients With Coronary ISR

This is an interventional treatment trial for Coronary Artery Disease Read More

Inclusion Criteria:

• General criteria

  1. Patient ≥18 years of age.
  2. Stable angina pectoris or unstable angina pectoris (acute coronary syndrome), prior myocardial infarction or proven asymptomatic myocardial ischemia.
  3. Patients are eligible for any type of coronary revascularization.
  4. Patients agree to receive angiography follow-up at 9 months after index procedure.
  5. Patients agree to receive clinical follow-up at 30 days, 6months, 9 months and 1years after index procedure.
  6. Patients are able to understand the purpose of the study and will comply with the study protocol. The patient is willing to sign informed consent form and understand the risks and benefits described in the informed consent form.

• lesion related

  1. Up to 2 ISR lesions which found by angiography (diameter stenosis ≥70% or ≥ 50% with evidence of ischemia) or functional examination (e.g. FFR<0.8 IVUS<4mm2) will be treated, target segment includes news lesions within 5mm of the stent margin.
  2. Up to 2 drug coated balloons (SeQuent® Please Neo or SeQuent® SCB) will be used in the study, with 1 drug coated balloon per lesion.
  3. ISR (including bare stents, inert and active drug eluting stents) : Mehran type I, II and III stenosis; The reference vessel diameter of target lesions ranges from 2.5mm to 4.0mm (visual), and the length of each lesion are≤ 34mm (visual).
  4. Other de novo lesions needing treatment must be >10mm away from the target lesion.

Exclusion Criteria:

• General criteria

  1. Patients with myocardial infarction within 1 week before index procedure.
  2. Patients with takayasu arteritis.
  3. Patients with severe renal failure, whose Creatinine >2.0 mg/dL (177 mol/L).
  4. LVEF<30%.
  5. Hb before procedure <10 g/dL.
  6. Patients with Coagulation disorder, platelet count <100,000/mm3.
  7. Patients with cardiogenic shock.
  8. Patients with diseases who require cytostatic or radiotherapy.
  9. Patients who are known to be allergic or contraindicated to aspirin, heparin, clopidogrel, rapamycin, ticagrelor, tirofiban, paclitaxel, or iopromide , or who are allergic to contrast agents and cannot be medically prevented, or who are on cilostazol anticoagulants.
  10. Patients with bleeding conditions, or with conditions that increase the risk of bleeding, such as gastrointestinal ulcers, which may be restricted or prohibited from anticoagulant therapy or the use of anticoagulant drugs.
  11. Gestational women who were pregnant before receiving treatment with the study device or who planned to be pregnant during the study , and did not use effective contraception until (including) follow-up at 12 months postoperatively; Female patients during lactation.
  12. Patients with a life expectancy less than 1 year.
  13. Patients who are participating in any other clinical trial.
  14. Investigator considered the patients ineligible due to any reasons.

• lesion related

  1. There are more than 3 lesions to be treated (including non-target lesions to be treated), and there are more than 2 lesions to be treated in each coronary artery.
  2. There will be more than 5 stents implanted in coronary artery after intervention (including previous and current PCI).
  3. After pre-dilatation of target lesion, there will be residual stenosis of target lesion >30% or TIMI blood flow < grade 3, and/ dissections NHLBI grade C,D,E,F.
  4. The ISR lesion has been treated in past 6 months.
  5. The target lesion is tortuous, severely calcified, angular, and the DCB is expected to be impassable.
  6. Target lesion contains thrombosis.
  7. Target or non-target lesion(s) located in left main.
  8. Patients with previous CABG.
  9. Patients with lesions requiring intervention treatment in 3 vessels